Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DS-Cav1
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
DS-Cav1 is a stabilized prefusion RSV F subunit protein vaccine developed for the prevention of Respiratory Syncytial Virus (RSV) infections. It contains the RSV A2 fusion glycoprotein ectodomain assembled as a prefusion-stabilized trimer and has been tested both alone and with aluminum hydroxide adjuvant. Clinical trials have shown it elicits robust neutralizing antibody responses that remain elevated for at least 44 weeks after vaccination.
- Other names
- RSV prefusion F protein vaccinestabilized prefusion RSV F subunit proteinVRC 317VRC317VRC-317
02
Targets
RSV preF (Respiratory syncytial virus prefusion F glycoprotein)
Beyond the preview
Go deeper on DS-Cav1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DS-Cav1.